Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Daridorexant Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,323Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Act-541468a, Act-541468 hydrochloride, Nemorexant hydrochloride, Quviviq, 9x9581n56r, 1792993-84-0
    Molecular Formula
    C23H24Cl2N6O2
    Molecular Weight
    487.4  g/mol
    InChI Key
    HJVGDXBEMFHGKI-BQAIUKQQSA-N
    FDA UNII
    9X9581N56R
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone;hydrochloride
    2.1.2 InChI
    InChI=1S/C23H23ClN6O2.ClH/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30;/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28);1H/t23-;/m0./s1
    2.1.3 InChI Key
    HJVGDXBEMFHGKI-BQAIUKQQSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl.Cl
    2.1.5 Isomeric SMILES
    CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    9X9581N56R
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Act-541468a

    2. Act-541468 Hydrochloride

    3. Nemorexant Hydrochloride

    4. Quviviq

    5. 9x9581n56r

    6. 1792993-84-0

    7. Unii-9x9581n56r

    8. Daridorexant Hydrochloride [usan]

    9. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)-, Hydrochloride (1:1)

    10. Chembl4650216

    11. Schembl16767284

    12. Ex-a7813

    13. Daridorexant Hydrochloride [jan]

    14. Ts-09376

    15. Daridorexant Hydrochloride [who-dd]

    16. ((2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5- Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone Hydrochloride (1:1)

    17. ((2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone Hydrochloride (1:1)

    18. ((2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone Monohydrochloride

    19. (s)-(2-(5-chloro-4-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone Hydrochloride

    2.4 Create Date
    2015-06-29
    3 Chemical and Physical Properties
    Molecular Weight 487.4 g/mol
    Molecular Formula C23H24Cl2N6O2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass g/mol
    Monoisotopic Mass g/mol
    Topological Polar Surface Area88.9
    Heavy Atom Count33
    Formal Charge0
    Complexity693
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    N05